This promotional website is for Healthcare Professionals.

Prescribing information is linked at the top of the page

Reporting adverse events.

Logo CSL Vifor
Background
Background

VELTASSA®

(patiromer)

One simple step to overall K+ control

Prescribing information

Veltassa® is indicated for the treatment of hyperkalemia in adults and adolescents aged 12–17 years.1 Please refer to the Summary of Product Characteristics for full prescribing information.

Supported icon

Supported by
real-world evidence2

Check icon

Proven K+ control3–8

Hands with heart

Designed for patients1,9–11

Thumbanil

Exchange K+ and discover
the benefits of Veltassa®’s mechanism of action

Click below to to learn more about how Veltassa® works

Play
Icon arrow right
Thumbnail

Address the complexities of hyperkalemia management

For patients who have been prescribed Veltassa®, follow these simple steps for administration

View now
Arrow down icon
Thumbnail

Veltassa® offers easy and convenient once-daily dosing from the start

For patients who have been prescribed Veltassa®, follow these simple steps for administration

Watch video
Icon arrow right
Thumbnail

Consistent and sustained
K+ control with once-daily treatment for hyperkalemia
in adults and adolescents

Discover how Veltassa® works

Watch video
Icon arrow right

References & footnotes

Referencedownarrow

Footnotes

Printed SmPC available upon request at the booth, abbreviated SmPC available at the content corner at the booth.

Veltassa® is approved in the European Union, Iceland, Norway, Switzerland and the United Kingdom. Best efforts have been undertaken to ensure compliance with EFPIA Code and the EU SmPC. The SmPC can vary from country to country; before prescribing, always refer to the applicable local SmPC.

Abbreviations

HK, hyperkalemia; K+, potassium; Na+, sodium; RAASi, renin-angiotensin-aldosterone system inhibitors; SAE, serious adverse event; SmPC, Summary of Product Characteristics.

References

  1. Veltassa® European SmPC, June 2024.
  2. Obi Y, et al. Kidney Med. 2023;6(1):100757. 
  3. Butler J, et al. Eur J heart Fail. 2022;24(1):230–8.
  4. Weir MR, et al. N Engl J Med. 2015;372(3):211–21.
  5. Agarwal R, et al. Lancet. 2019;394:1540–50. 
  6. Pitt B, et al. Eur Heart J. 2011;32:820–8.
  7. Di Palo KE, et al. JAMA Netw Open. 2022;5(1):e2145236.
  8. Bakris GL, et al. JAMA. 2015;314(2):151–61. 
  9. Li L, et al. J Cardiovasc Pharmacol Ther. 2016;21(5):456–65.
  10. Brenner M, et al. Poster P4-075, American Society of Health System Pharmacists Annual Meeting. Las Vegas, NV. 
  11. Wheeler DC, et al. BMJ Open. 2024;14(2):e074954.

HQ-PAT-2500029 | Date of preparation: May 2025

Adverse events should be reported.
All Healthcare Professionals must report Adverse Events and special situations associated with CSL Vifor products, within 24 hours of receipt of the information when they become aware or are informed about it, to Global Drug Safety at safety@viforpharma.com. Medicinal product subject to restricted medical prescription. Full prescribing information is available on request. Please read the full SmPC prior to administration and please refer to the latest version available. Please contact our company for detailed information.